S
Sergio Mantegani
Researcher at Pfizer
Publications - 19
Citations - 505
Sergio Mantegani is an academic researcher from Pfizer. The author has contributed to research in topics: Ergoline & Heat shock protein. The author has an hindex of 9, co-authored 19 publications receiving 476 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of protein–protein interactions: The discovery of druglike β-catenin inhibitors by combining virtual and biophysical screening
Jean-Yves Trosset,Claudio Dalvit,Stefan Knapp,Marina Fasolini,Marina Veronesi,Sergio Mantegani,Laura Gianellini,Cornel Catana,Michael Sundström,Pieter F. W. Stouten,Jürgen K. Moll +10 more
TL;DR: The interaction between β‐catenin and Tcf family members is crucial for the Wnt signal transduction pathway, which is commonly mutated in cancer, and inhibiting such interactions using low molecular weight inhibitors is a challenge.
Journal ArticleDOI
Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.
Daniele Fancelli,D. Berta,Simona Bindi,Alexander D. Cameron,Paolo Cappella,Patrizia Carpinelli,Cornel Catana,Barbara Forte,Patrizia Giordano,Maria Laura Giorgini,Sergio Mantegani,Aurelio Marsiglio,M. Meroni,Juergen Moll,Valeria Pittalà,Fulvia Roletto,Dino Severino,Chiara Soncini,Paola Storici,Roberto Tonani,Mario Varasi,and Anna Vulpetti,Paola Vianello +22 more
TL;DR: Potent and selective Aurora kinase inhibitors were identified from the combinatorial expansion of the 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole bi-cycle, a novel and versatile scaffold designed to target the ATP pocket of protein kinases.
Journal ArticleDOI
Synthesis and nidation inhibitory activity of a new class of ergoline derivatives
TL;DR: In this article, the synthesis and inhibitory activity of ergolinyl-acylureas is described and some structure-activity relationship relationship considerations are also reported, and a new class of ergoline-8β-carboxamide is described.
Journal ArticleDOI
NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases
Gianpaolo Fogliatto,Laura Gianellini,Maria Gabriella Brasca,Elena Casale,Dario Ballinari,Marina Ciomei,Anna Degrassi,Anna De Ponti,Massimiliano Germani,Marco Guanci,Mauro Paolucci,Paolo Polucci,M. Russo,Francesco Sola,Barbara Valsasina,Carlo Visco,Fabio Zuccotto,Daniele Donati,Eduard R. Felder,Enrico Pesenti,Arturo Galvani,Sergio Mantegani,Antonella Isacchi +22 more
TL;DR: The efficacy profile of NMS-E973 suggests a potential for development in different clinical settings, including tumors that have become resistant to molecular targeted agents, particularly in cases of tumors which reside beyond the BBB.
Journal ArticleDOI
Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
Maria Gabriella Brasca,Sergio Mantegani,Nadia Amboldi,Simona Bindi,Dannica Caronni,Elena Casale,Walter Ceccarelli,Nicoletta Colombo,Anna De Ponti,Daniele Donati,Antonella Ermoli,Gabriele Fachin,Eduard R. Felder,Ferguson Ron,Claudio Fiorelli,Marco Guanci,Antonella Isacchi,Enrico Pesenti,Paolo Polucci,Laura Riceputi,Francesco Sola,Carlo Visco,Fabio Zuccotto,Gianpaolo Fogliatto +23 more
TL;DR: The identification of compound 18 (NMS-E973), which displayed significant efficacy in a human ovarian A2780 xenograft tumor model, with a mechanism of action confirmed in vivo by typical modulation of known Hsp90 client proteins, and with a favorable pharmacokinetic and safety profile.